Article

Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapy

2023-12-05

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background and Objective</h4> People with multiple sclerosis (pwMS) receiving B cell-depleting therapies have impaired antibody responses to vaccination. In a proportion of individuals, repeat vaccination against COVID-19 leads to seroconversion. We sought to describe the immune phenotype of pwMS on ocrelizumab, and identify clinical and immunological determinants of an effective vaccine resp...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 82b605e4-2e61-5c4f-b8f3-3da94e986906
DOI: 10.1101/2023.12.04.23299409

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapyDOI 10.1101/2023.12.04.23299409Read

Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinationsSemantic proximity Read

T cell responses to SARS-CoV-2 vaccination in people with multiple sclerosis differ between disease-modifying therapiesSemantic proximity Read

Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapySemantic proximity Read

Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patientsSemantic proximity Read

Response to COVID-19 booster vaccinations in seronegative people with MSSemantic proximity Read

Distinct Patterns of Humoral and Cellular Immune Responses Following SARS-CoV-2 mRNA Vaccination in Patients With Immune-Mediated Neurological Disorders on Anti-CD20 Therapy: A Prospective Cohort StudySemantic proximity Read

Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccinesSemantic proximity Read

Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapySemantic proximity Read

Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.Semantic proximity Read

Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273Semantic proximity Read

Longitudinal follow-up of SARS-CoV-2 vaccine- induced antibody responses in patients with multiple sclerosis treated with anti-CD20 therapySemantic proximity Read

SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumabSemantic proximity Read